Fortrea Holdings (FTRE) Non-Current Deferred Tax Liability (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Non-Current Deferred Tax Liability came in at $97.0 million in Q2 2026, down 14.01% on a YoY basis from $112.8 million in Q2 2025, and up 5.09% quarter-over-quarter from $92.3 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has reported Non-Current Deferred Tax Liability for 5 consecutive years, with $97.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Deferred Tax Liability fell 14.01% year-over-year to $97.0 million; the trailing twelve-month figure through Jun 2026 stood at $97.0 million (down 14.01% YoY), and the FY2025 full-year result was $97.6 million, down 19.8% from the prior year.
- Non-Current Deferred Tax Liability improved to $97.0 million in Q2 2026 per FTRE's latest filing, from $92.3 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $184.5 million in Q4 2022 and bottomed at $92.3 million in Q1 2026.
- Historically, Non-Current Deferred Tax Liability has averaged $132.0 million across 5 years, with a median of $124.3 million in 2024.
- The sharpest annual moves came in 2024 and 2026: Non-Current Deferred Tax Liability slipped 26.11% in 2024, then declined 14.01% in 2026.
- Over 5 years, Non-Current Deferred Tax Liability stood at $184.5 million in 2022, then fell by 19.95% to $147.7 million in 2023, then decreased by 17.6% to $121.7 million in 2024, then decreased by 19.8% to $97.6 million in 2025, then slipped by 0.61% to $97.0 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $97.0 million, $92.3 million, and $97.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.06 Bn | 42.11 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn |
| 3 | Charles River Laboratories International | 13.77 Bn | 13.62 Bn | 452.07 Mn |
| 4 | Icon | 12.62 Bn | 11.69 Bn | 479.29 Mn |
| 5 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn |
| 6 | Evotec SE | 661.34 Mn | 235.46 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 442.79 Mn | 358.26 Mn | 18.44 Mn |
| 8 | Champions Oncology | 72.49 Mn | 72.62 Mn | 7.03 Mn |
| 9 | MindWalk Holdings | 61.66 Mn | 53.38 Mn | 1.82 Mn |
| 10 | VivoSim Labs | 1.47 Mn | 1.47 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 97.00 Mn |
| Mar 31, 2026 | 92.30 Mn |
| Dec 31, 2025 | 97.60 Mn |
| Sep 30, 2025 | 106.90 Mn |
| Jun 30, 2025 | 112.80 Mn |
| Mar 31, 2025 | 117.90 Mn |
| Dec 31, 2024 | 121.70 Mn |
| Sep 30, 2024 | 126.90 Mn |
| Jun 30, 2024 | 136.10 Mn |
| Mar 31, 2024 | 150.70 Mn |
| Dec 31, 2023 | 147.70 Mn |
| Sep 30, 2023 | 171.70 Mn |
| Jun 30, 2023 | 184.20 Mn |
| Dec 31, 2022 | 184.50 Mn |